Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

A medication called omalizumab (often sold as Xolair) has been around for a long time and was used to help deal with asthma.

Kashiv BioSciences, LLC today announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab).

“The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase ...

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

The Food and Drug Administration (FDA) has approved Omlyclo ® (omalizumab-igec), the first interchangeable biosimilar to Xolair ® (omalizumab).. Omlyclo, formerly known as CT-P39, is an anti ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 ...

Omalizumab is also considered unique, as it is safe for children as young as one year olds. Currently, there is only one additional FDA-approved treatment for food allergy—it’s an oral ...

Omalizumab is also considered unique, as it is safe for children as young as 1-year-olds. Currently, there is only one additional FDA-approved treatment for food allergy ...